Therapeutic effects of monoclonal antibody g250, interferons and tumor necrosis factor, in mice with renal‐cell carcinoma xenografts

No abstract is available for this paper.

• Publication year

  1994

• Venue

  International Journal of Cancer

• Publication date

  1994-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.2910560220PMID 8314310
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations

  2004cited by this paper
• Establishment and characterization of five new human renal tumor xenografts.

  1992cited by this paper
• An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice.

  1992cited by this paper
• Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.

  1992cited by this paper
• HLA‐class‐I and‐class‐II expression on renal tumor xenografts and the relation to sensitivity for α‐IFN, γ‐IFN and TNF

  1991cited by this paper
• Tumor cell lysis and tumor growth inhibition by the isotype variants of MAb BR55-2 directed against Y oligosaccharide.

  1991cited by this paper
• HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF.

  1991cited by this paper
• Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal‐cell carcinoma xenografts: Relative effects of size and affinity

  1991cited by this paper
• Recombinant alpha-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo.

  1990cited by this paper
• Mechanisms of macrophage‐mediated tumor cell killing: A comparative analysis of the roles of reactive nitrogen intermediates and tumor necrosis factor

  1990cited by this paper
• Direct evidence for an intracellular role for IFN-gamma. Microinjection of human IFN-gamma induces Ia expression on murine macrophages.

  1990cited by this paper
• Antiproliferative and cytotoxic effects of single and combined treatment with tumor necrosis factor alpha and/or alpha interferon on a human renal cell carcinoma xenotransplanted into nu/nu mice: cell kinetic studies.

  1990cited by this paper
• Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.

  1990cited by this paper
• Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies.

  1990cited by this paper
• Induction of tumor‐cell lysis by bi‐specific monoclonal antibodies recognizing renal‐cell carcinoma and cd3 antigen

  1989cited by this paper
• In Vitro Sensitivity of Three Human Renal Tumor Xenografts Towards Tumor Necrosis Factor and Alpha and Gamma Interferon

  1989cited by this paper
• Biological response modifiers: the new immunotherapy.

  1989cited by this paper
• Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review.

  1989cited by this paper
• Effects of monoclonal antibody, recombinant interferon-gamma, and tumor necrosis factor-alpha in the treatment of human melanoma xenografts.

  1989cited by this paper
• Tumor necrosis factor: how to improve the antitumor activity and decrease accompanying side effects for therapeutic application.

  1988cited by this paper
• Synergistic Growth‐Inhibitory Activity of Tumour Necrosis Factor and Alpha Interferon Contribution to the Monocyte‐Derived Cytostatic Activity towards Human Leukaemia K562 Cells

  1988cited by this paper
• Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.

  1988cited by this paper
• A phase I clinical trial of recombinant human tumor necrosis factor

  1988cited by this paper
• Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro.

  1988cited by this paper
• Tumor Necrosis Factor‐α Induces Increased Hydrogen Peroxide Production and Fc Receptor Expression, but Not Increased la Antigen Expression by Peritoneal Macrophages

  1987cited by this paper
• Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.

  1987cited by this paper
• Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo.

  1987cited by this paper
• The effect of interferon on experimental metastases in immunocompetent and immunodeficient mice

  1986cited by this paper
• Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation.

  1986cited by this paper
• Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidney

  1986cited by this paper
• Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons.

  1986cited by this paper
• The interaction of murine IgG subclass proteins with human monocyte Fc receptors.

  1985cited by this paper
• Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis.

  1984cited by this paper
• Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?

  1984cited by this paper
• Monoclonal antibodies with different specificities against cytokeratins. An immunohistochemical study of normal tissues and tumors.

  1984cited by this paper
• The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity.

  1982cited by this paper

• CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target

  2018cites this paper
• A Novel Hypoxia Imaging Endoscopy System

  2017cites this paper
• The Use of Monoclonal Antibody G 250 in the Therapy of Renal-Cell Carcinoma

  2017cites this paper
• Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma

  2015cites this paper
• Carbonic Anhydrase IX and Monoclonal Antibody G250: Relevance as a Clinical and Biologic Target in Renal Cell Carcinoma

  2015cites this paper
• Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment.

  2014cites this paper
• PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

  2014cites this paper
• Potential role of 124 I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

  2012cites this paper
• Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

  2012cites this paper
• Tumor Hypoxia Imaging

  2011cites this paper
• Carbonic Anhydrase IX: Biology and Clinical Approaches

  2009cites this paper
• Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies.

  2008cites this paper
• Radiolabeled antibodies in renal cell carcinoma

  2007cites this paper
• G250: A carbonic anhydrase IX monoclonal antibody

  2005cites this paper
• Monoclonal antibody-based therapy for renal cell carcinoma.

  2003cites this paper
• Monoclonal antibody therapy of kidney cancer.

  2003cites this paper
• Biodistribution and pharmacokinetics of 125I‐labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma

  2003cites this paper
• Identification of markers for the selection of patients undergoing renal cell carcinoma‐specific immunotherapy

  2003cites this paper
• Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.

  2003cites this paper
• Complement-mediated killing of cancer cells

  2003cites this paper
• Quantification of G250 mRNA expression in renal epithelial neoplasms by real‐time reverse transcription‐PCR of dissected tissue from paraffin sections

  2003cites this paper
• Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model.

  2003cites this paper
• Interferons Can Upregulate the Expression of the Tumor Associated Antigen G250-MN/CA IX, a Potential Target for (Radio)Immunotherapy of Renal Cell Carcinoma

  2003cites this paper
• A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.

  2003cites this paper
• Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?

  2002cites this paper
• Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.

  2001cites this paper
• Molecular-based therapies for renal cell carcinoma

  2001cites this paper
• Vaccines in urologic malignancies

  2001cites this paper
• Renal Cell Carcinoma and Interferon at the Millennium

  2001cites this paper
• Prognostic S ignificance o f a N ovel H ypoxia-Regulate d Marker, C arbonic A nhydrase I X, i n I nvasive B reast Carcinoma

  2001cites this paper
• Immune-gene therapy for renal cancer: chimeric receptor-mediated lysis of tumor cells

  2001cites this paper
• Immune and genetic therapies for advanced renal cell carcinoma.

  2000cites this paper
• MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas

  1999cites this paper
• Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.

  1999cites this paper
• Monoclonal antibodies against renal tumors: the potential application in discrimination of ambiguous adenocarcinoma or transitional cell carcinoma of kidney.

  1998cites this paper
• Gene therapy--the future is here: a guide to the practicing urologist.

  1998cites this paper
• Chimeric immunoglobulin E reactive with tumor-associated antigen activates human FcεRI bearing cells

  1997cites this paper
• Anti-Idiotype Antibodies in Renal Cell Carcinoma

  1997cites this paper
• Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.

  1996cites this paper
• Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines.

  1996cites this paper
• Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.

  1996cites this paper
• Gamma-interferon induces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma.

  1996cites this paper
• Induction of tumor regression by passive transfer of antibody from mice vaccinated with anti-idiotype antibodies resembling a human renal cell carcinoma-associated antigen.

  1995cites this paper
• Tumor Heterogeneity and Immunotherapy of Cancer

  1995influential citation
• The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma.

  1995cites this paper
• Internal image anti-idiotype antibodies related to G250 antigen: potential tools for specific immunotherapy in human renal cell carcinoma

  1994cites this paper
• Internal image anti‐idiotype antibodies related to renal‐cell carcinoma‐associated antigen G250

  1994cites this paper
• Vaccination with ant‐idiotype antibodies mimicking a renal cell carcinoma‐associated antigen induces tumor immunity

  1994cites this paper